WO2016200614A3 - Bacteria engineered to treat diseases associated with hyperammonemia - Google Patents

Bacteria engineered to treat diseases associated with hyperammonemia Download PDF

Info

Publication number
WO2016200614A3
WO2016200614A3 PCT/US2016/034200 US2016034200W WO2016200614A3 WO 2016200614 A3 WO2016200614 A3 WO 2016200614A3 US 2016034200 W US2016034200 W US 2016034200W WO 2016200614 A3 WO2016200614 A3 WO 2016200614A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyperammonemia
diseases associated
treat diseases
bacteria engineered
bacteria
Prior art date
Application number
PCT/US2016/034200
Other languages
French (fr)
Other versions
WO2016200614A2 (en
Inventor
Dean Falb
Vincent M. ISABELLA
Jonathan W. KOTULA
Paul F. Miller
Suman MACHINANI
Original Assignee
Synlogic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/960,333 external-priority patent/US9487764B2/en
Priority claimed from PCT/US2016/020530 external-priority patent/WO2016141108A1/en
Priority to EP16731402.0A priority Critical patent/EP3307879A2/en
Priority to AU2016274311A priority patent/AU2016274311A1/en
Priority to CA2988930A priority patent/CA2988930A1/en
Priority to JP2017564379A priority patent/JP6817966B2/en
Application filed by Synlogic, Inc. filed Critical Synlogic, Inc.
Publication of WO2016200614A2 publication Critical patent/WO2016200614A2/en
Priority to US16/069,220 priority patent/US11723932B2/en
Priority to EP17703255.4A priority patent/EP3402498A1/en
Priority to PCT/US2017/013072 priority patent/WO2017123675A1/en
Priority to CA3011283A priority patent/CA3011283A1/en
Publication of WO2016200614A3 publication Critical patent/WO2016200614A3/en
Priority to PCT/US2017/017552 priority patent/WO2017139697A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/10—Citrulline; Arginine; Ornithine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Abstract

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
PCT/US2016/034200 2015-06-10 2016-05-25 Bacteria engineered to treat diseases associated with hyperammonemia WO2016200614A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP16731402.0A EP3307879A2 (en) 2015-06-10 2016-05-25 Bacteria engineered to treat diseases associated with hyperammonemia
AU2016274311A AU2016274311A1 (en) 2015-06-10 2016-05-25 Bacteria engineered to treat diseases associated with hyperammonemia
CA2988930A CA2988930A1 (en) 2015-06-10 2016-05-25 Bacteria engineered to treat diseases associated with hyperammonemia
JP2017564379A JP6817966B2 (en) 2015-06-10 2016-05-25 Bacteria engineered to treat diseases associated with hyperammonemia
CA3011283A CA3011283A1 (en) 2016-01-11 2017-01-11 Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
US16/069,220 US11723932B2 (en) 2016-01-11 2017-01-11 Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
PCT/US2017/013072 WO2017123675A1 (en) 2016-01-11 2017-01-11 Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
EP17703255.4A EP3402498A1 (en) 2016-01-11 2017-01-11 Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
PCT/US2017/017552 WO2017139697A1 (en) 2016-02-10 2017-02-10 Bacteria engineered to treat diseases associated with hyperammonemia

Applications Claiming Priority (30)

Application Number Priority Date Filing Date Title
US201562173710P 2015-06-10 2015-06-10
US201562173706P 2015-06-10 2015-06-10
US62/173,710 2015-06-10
US62/173,706 2015-06-10
US201562183935P 2015-06-24 2015-06-24
US62/183,935 2015-06-24
US201562184811P 2015-06-25 2015-06-25
US201562184770P 2015-06-25 2015-06-25
US62/184,770 2015-06-25
US62/184,811 2015-06-25
US201562248805P 2015-10-30 2015-10-30
US62/248,805 2015-10-30
US201562256039P 2015-11-16 2015-11-16
US201562256048P 2015-11-16 2015-11-16
US201562256041P 2015-11-16 2015-11-16
US62/256,039 2015-11-16
US62/256,048 2015-11-16
US62/256,041 2015-11-16
US201562263329P 2015-12-04 2015-12-04
US14/960,333 US9487764B2 (en) 2014-12-05 2015-12-04 Bacteria engineered to treat diseases associated with hyperammonemia
US62/263,329 2015-12-04
US14/960,333 2015-12-04
US201662277654P 2016-01-12 2016-01-12
US62/277,654 2016-01-12
US201662291468P 2016-02-04 2016-02-04
US62/291,468 2016-02-04
US201662293749P 2016-02-10 2016-02-10
US62/293,749 2016-02-10
USPCT/US16/020530 2016-03-02
PCT/US2016/020530 WO2016141108A1 (en) 2015-03-02 2016-03-02 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2016/032556 Continuation WO2016183529A1 (en) 2015-05-13 2016-05-13 Translating machine codes to store metadata and to propagate metadata for run time checking of programming errors
PCT/US2016/032565 Continuation-In-Part WO2016183532A1 (en) 2014-12-05 2016-05-13 Bacteria engineered to treat a disease or disorder

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/164,828 Continuation-In-Part US9688967B2 (en) 2014-12-05 2016-05-25 Bacteria engineered to treat diseases associated with hyperammonemia
US16/069,220 Continuation US11723932B2 (en) 2016-01-11 2017-01-11 Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells

Publications (2)

Publication Number Publication Date
WO2016200614A2 WO2016200614A2 (en) 2016-12-15
WO2016200614A3 true WO2016200614A3 (en) 2017-01-12

Family

ID=57504262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/034200 WO2016200614A2 (en) 2015-06-10 2016-05-25 Bacteria engineered to treat diseases associated with hyperammonemia

Country Status (5)

Country Link
EP (1) EP3307879A2 (en)
JP (2) JP6817966B2 (en)
AU (1) AU2016274311A1 (en)
CA (1) CA2988930A1 (en)
WO (1) WO2016200614A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136795A1 (en) 2016-02-04 2017-08-10 Synlogic, Inc. Bacteria engineered to treat diseases associated with tryptophan metabolism
US20210145946A1 (en) * 2017-01-24 2021-05-20 Thoeris Gmbh Use of glutamine synthetase for treating hyperammonemia
CN111918960A (en) * 2017-12-05 2020-11-10 比奥普来克斯有限公司 Methods and compositions for preventing microbial infections
CN110446259B (en) * 2018-05-04 2022-04-15 大唐移动通信设备有限公司 Position determination method of paging opportunity and communication equipment
EP3963046A1 (en) 2019-04-29 2022-03-09 Synlogic Operating Company, Inc. Enumeration of genetically engineered microorganisms by live cell counting techniques
WO2020239882A1 (en) 2019-05-30 2020-12-03 Recordati Industria Chimica E Farmaceutica S.P.A. Pharmaceutical formulation for carglumic acid
WO2020247594A1 (en) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
WO2021107500A1 (en) 2019-11-29 2021-06-03 주식회사 지니스 Strain having ability to lower blood ammonia levels and composition comprising same for neuronal protection
CN116670269A (en) 2020-12-02 2023-08-29 同生运营公司 Engineered microorganisms
KR20230151530A (en) 2021-03-31 2023-11-01 닛폰세이테츠 가부시키가이샤 Non-oriented electrical steel sheet, punching method for non-oriented electrical steel sheet, and mold for punching non-oriented electrical steel sheet

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3083315B2 (en) * 1990-10-29 2000-09-04 株式会社ヤクルト本社 Blood ammonia lowering agent
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
IT1290679B1 (en) * 1997-02-14 1998-12-10 Alfa Wassermann Spa USE OF RIFAXIMINE AND OF THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT IN THE TREATMENT OF DIARRHEA FROM CRYPTOSPORIDIOSIS.
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1135461A4 (en) 1998-12-02 2003-03-26 Univ Boston Gene networks for control of gene expression
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
WO2009123029A1 (en) * 2008-03-31 2009-10-08 株式会社 大塚製薬工場 Blood ammonia level regulator
AU2014331610B2 (en) * 2013-10-03 2019-11-07 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
AKAWI LAMEES ET AL: "Engineering Escherichia coli for high-level production of propionate", JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY, vol. 42, no. 7, July 2015 (2015-07-01), pages 1057 - 1072, XP002761846 *
BAEK J-M ET AL: "Butyrate production in engineered Escherichia coli with synthetic scaffolds", BIOTECHNOLOGY AND BIOENGINEERING OCTOBER 2013 JOHN WILEY AND SONS INC. USA, vol. 110, no. 10, October 2013 (2013-10-01), pages 2790 - 2794, XP002761845, DOI: 10.1002/BIT.24925 *
BARTSCH K ET AL: "Molecular analysis of two genes of the Escherichia coli gab cluster: nucleotide sequence of the glutamate:succinic semialdehyde transaminase gene (gabT) and characterization of the succinic semialdehyde dehydrogenase gene (gabD)", JOURNAL OF BACTERIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 172, no. 12, 1 December 1990 (1990-12-01), pages 7035 - 7042, XP002608068, ISSN: 0021-9193 *
BRECHTEL CASEY E ET AL: "Substrate specificity of the Escherichia coli 4-aminobutyrate carrier encoded by gabP: Uptake and counterflow of structurally diverse molecules", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 2, 1996, pages 783 - 788, XP002761843, ISSN: 0021-9258 *
CALDARA ET AL.: "Arginine biosynthesis in Escherichia coli: experimental perturbation and mathematical modeling", J BIOL CHEM., vol. 283, no. 10, 7 March 2008 (2008-03-07), pages 6347 - 6358, XP002755885 *
CASTAGIUOLO I ET AL: "Engineered E. coli delivers therapeutic genes to the colonic mucosa", GENE THERAPY, NATURE PUBLISHING GROUP, GB, vol. 12, 1 January 2005 (2005-01-01), pages 1070 - 1078, XP003009139, ISSN: 0969-7128, DOI: 10.1038/SJ.GT.3302493 *
CHEN ZHONGYI ET AL: "Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity", JOURNAL OF CLINICAL INVESTIGATION, vol. 124, no. 8, August 2014 (2014-08-01), pages 3391 - 3406, XP002761847 *
HAN Q ET AL: "Kynurenine aminotransferase and glutamine transaminase K of Escherichia coli: Identity with aspartate aminotransferase", BIOCHEMICAL JOURNAL 20011215 PORTLAND PRESS LTD GB, vol. 360, no. 3, 15 December 2001 (2001-12-15), pages 617 - 623, XP002761842, DOI: 10.1042/0264-6021:3600617 *
HANSON MIRANDA L ET AL: "Oral Delivery of IL-27 Recombinant Bacteria Attenuates Immune Colitis in Mice", GASTROENTEROLOGY, vol. 146, no. 1, January 2014 (2014-01-01), pages 210 - 221, XP002761850 *
MAKUI HORTENCE ET AL: "Identification of the Escherichia coli K-12 Nramp orthologue (MntH) as a selective divalent metal ion transporter", MOLECULAR MICROBIOLOGY, vol. 35, no. 5, March 2000 (2000-03-01), pages 1065 - 1078, XP002761844, ISSN: 0950-382X *
MOTTA JEAN-PAUL ET AL: "Food-Grade Bacteria Expressing Elafin Protect Against Inflammation and Restore Colon Homeostasis", SCIENCE TRANSLATIONAL MEDICINE, vol. 4, no. 158, October 2012 (2012-10-01), XP002761849 *
RAJAGOPAL B S ET AL: "Use of inducible feedback-resistant N-acetylglutamate synthetase (argA) genes for enhanced arginine biosynthesis by genetically engineered Escherichia coli K-12 strains", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 64, no. 5, 1 May 1998 (1998-05-01), pages 1805 - 1811, XP002169946, ISSN: 0099-2240 *
VOLKER ALEXANDRA R ET AL: "Fermentative production of short-chain fatty acids in Escherichia coli", MICROBIOLOGY (READING), vol. 160, no. Part 7, July 2014 (2014-07-01), pages 1513 - 1522, XP002761848, ISSN: 1350-0872 *
YUEH-MEI CHENG ET AL: "Functional expression of recombinant human trefoil factor 1 by Escherichia coli and Brevibacillus choshinensis", BMC BIOTECHNOLOGY, BIOMED CENTRAL LTD. LONDON, GB, vol. 15, no. 1, 20 May 2015 (2015-05-20), pages 32, XP021222771, ISSN: 1472-6750, DOI: 10.1186/S12896-015-0149-5 *

Also Published As

Publication number Publication date
JP2018523978A (en) 2018-08-30
CA2988930A1 (en) 2016-12-15
EP3307879A2 (en) 2018-04-18
AU2016274311A1 (en) 2018-01-18
WO2016200614A2 (en) 2016-12-15
JP6817966B2 (en) 2021-01-20
JP2021061846A (en) 2021-04-22

Similar Documents

Publication Publication Date Title
MX2021006581A (en) Bacteria engineered to treat diseases associated with hyperammonemia.
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia
WO2017139697A8 (en) Bacteria engineered to treat diseases associated with hyperammonemia
WO2016210384A3 (en) Bacteria engineered to treat metabolic diseases
WO2017136795A8 (en) Bacteria engineered to treat diseases associated with tryptophan metabolism
WO2016172658A3 (en) Microbiome regulators and related uses thereof
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
WO2016183532A8 (en) Bacteria engineered to treat a disease or disorder
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
BR112017024384A2 (en) bacteria modified to reduce hyperphenylalaninemia
WO2015168532A3 (en) Compositions and methods for modulating pkk expression
WO2016168592A3 (en) Compositions for modulating c9orf72 expression
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
PT3377637T (en) Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
WO2019099682A9 (en) Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains
WO2015077503A8 (en) Autotaxin inhibitor compounds
MX2019000588A (en) Somatostatin modulators and uses thereof.
PH12018500379A1 (en) Biopharmaceutical compositions
EP3483256A4 (en) Akkermansia muciniphila strain having effect of preventing or treating degenerative brain diseases or metabolic diseases, and use thereof
EP3160493A4 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
MX2017009417A (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof.
WO2016077639A3 (en) Nanovesicular therapies
WO2019040106A3 (en) Compounds, salts thereof and their use in the treatment of diseases
WO2015120372A3 (en) Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16731402

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2988930

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017564379

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016731402

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016274311

Country of ref document: AU

Date of ref document: 20160525

Kind code of ref document: A